Lirilumab
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | KIR2DL1/2/3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6452H9918N1698O2030S46 |
Molar mass | 145.2 kg/mol g·mol−1 |
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
Clinical trials
A phase 2 clinical trial for acute myeloid leukemia (AML)[4] was terminated early ("failed") in 2017.[5]
It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),[6] but it may be abandoned.[7]
As of November 2017 nine clinical trials of lirilumab are registered as active.[8]
References
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
- Romagné et al., Blood 2009 http://bloodjournal.hematologylibrary.org/content/114/13/2667.full.pdf Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
- Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)
- Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
- Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
- Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
- lirilumab trials
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.